On June 03, 2014, Atossa Genetics Inc (NASDAQ:ATOS), announced it has hired John E. Sawyer as Senior Vice President of Global Regulatory Affairs and Quality Assurance effective June 1, 2014. Atossa Genetics Inc (NASDAQ:ATOS), weekly performance is -4.08%. On last trading day company shares ended up $1.41. Analysts mean target price for the company is $8.75. Atossa Genetics Inc (NASDAQ:ATOS), distance from 50-day simple moving average (SMA50) is -0.09%.
On June 02, 2014, AcelRx Pharmaceuticals Inc (NASDAQ:ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, announced that David Chung has resigned as Chief Commercial Officer in order to assume the role of Chief Executive Officer of a medical device company. AcelRx Pharmaceuticals Inc (NASDAQ:ACRX), fell 5.14% in last trading session and ended the day on $8.30. ACRX, return on assets is -24.30%. AcelRx Pharmaceuticals Inc (NASDAQ:ACRX), quarterly performance is -30.37%.
On June, 06, 2014, Therapeutics Inc (USA) (NASDAQ:TTHI), announced that Jack W. Schuler, Larry N. Feinberg, Oracle Investment Management, certain Transition Board members, management and other existing shareholders will make an investment of up to US$30.8 million by purchasing 3,195,487 units of the Company at a price of US$5.32 per unit. Transition Therapeutics Inc (USA) (NASDAQ:TTHI), shares moved down 0.01% in last trading session and was closed at $5.50, while trading in range of $5.13 – 5.58. Transition Therapeutics Inc (USA) (NASDAQ:TTHI), year to date (YTD) performance is -3.34%.
Research analysts at Cowen and Company decreased their target price on shares of Hansen Medical, Inc. (NASDAQ:HNSN), from $3.00 to $2.50 in a report released on Tuesday. The firm currently has an “outperform” rating on the stock. Cowen and Company’s price target would suggest a potential upside of 89.39% from the company’s current price. Hansen Medical, Inc. (NASDAQ:HNSN), ended the last trading day at $1.40. Company weekly volatility is calculated as 5.25% and price to cash ratio as 4.75. Hansen Medical, Inc. (NASDAQ:HNSN), showed a negative weekly performance of 4.76%.
ZIOPHARM Oncology Inc. (NASDAQ:ZIOP), saw a large decline in short interest in April. As of April 30th, there was short interest totalling 18,661,854 shares, a decline of 9.9% from the April 15th total of 20,716,430 shares, Stock Ratings Network reports. Approximately 31.5% of the company’s stock are sold short. Based on an average daily volume of 1,068,926 shares, the short-interest ratio is presently 17.5 days. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP), weekly performance is 11.67%. On last trading day company shares ended up $4.02. Analysts mean target price for the company is $7.00. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP), distance from 50-day simple moving average (SMA50) is 10.72%.